Amgen acquires BioVex
The acquisition includes an investigational oncolytic vaccine in Phase 3 clinical development, OncoVex, as a new approach to treat melanoma, head and neck cancer. BioVex is also developing
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
Discovered and developed by Abbott scientists, Atrasentan is a selective endothelin-A receptor (ETAR) antagonist which is presently being investigated as a potential treatment for diabetic kidney disease. These